Stock Ratings / Health Care / APUS / insiders

XBIO (34) ADXN (46) CANF (26) PULM (36) ⌘ Pro Terminal →

Apimeds Pharmaceuticals US Inc. (APUS) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.21 +4.56% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.23

Apimeds Pharmaceuticals US Inc. (APUS) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $5.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on APUS Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Apimeds Pharmaceuticals US Inc. (NYSE: APUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $3.21 (+4.56% 1D, market cap $5.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, APUS ranks #622 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does APUS compare to XBIO and ADXN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APUS carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -6.2%. By comparison, XBIO (Xenetic Biosciences Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -30.3%, cap $5.0M) and ADXN (Addex Therapeutics Ltd) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $5.0M). Among the 5-stock peer group, APUS leads on earnings multiple (N/A) while APUS leads on capital efficiency (-6.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for APUS?

▼

Per APUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001894525), Apimeds Pharmaceuticals US Inc. generated $0 in revenue, -$6.0M in net income, and -$9.0M in free cash flow against $164.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.23 (+0.63%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-9.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APUS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY APUS SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+11/20 pts (30% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 44.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$5.20-32.7% Next Q

Q2 (-2Q)

Grade D$3.50-17.4% Next Q

Q3 (-1Q)

Grade D$2.89+11.1% Next Q

Current

Grade D-$3.21-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a APUS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While APUS currently carries a cautious 37/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.66) and Max Pain ($3.37) forces dealer call-delta covering toward $62.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $APUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “APUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

APUS Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (APUS)

No recent open-market Form 4 cluster sales or emergency dumps flagged on APUS. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APUS)

✓Walkthrough of APUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.93%🛡️ HOLDING TREND SUPPORT

2026-11-02O $3.07H $3.21L $3.07C $3.21VOL 50.1K

RES: $12.32SUP: $-1.21SMA50: $3.66SMA200: $10.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APUS Butterfly Map → + Track APUS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APUS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APUS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APUS)

Health Care Rank #622 of 1016 ⚔️ XBIO vs APUS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APUS vs. XBIO, ADXN, CANF, PULM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apimeds Pharmaceuticals US Inc. (APUS) ranks #622 by composite RQD confidence (37/100, grade D-) and #949 by equity capitalization ($5.0M). Within this direct 5-issuer industry benchmark cohort, APUS leads on earnings valuation at N/A trailing P/E, while APUS leads on capital efficiency and profitability with -6.2% ROIC and — gross margin. ADXN currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with APUS at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APUS ACTIVE Apimeds Pharmaceuticals US Inc.	D-	37/100	—	—	-6.2%	+4.56%	$5.0M	Benchmark Subject
XBIO Xenetic Biosciences Inc.	E	34/100	—	—	-30.3%	+0.95%	$5.0M	/xbio-vs-apus →
ADXN Addex Therapeutics Ltd	D	46/100	—	—	—	-1.01%	$5.0M	/adxn-vs-apus →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	26/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-apus →
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-apus →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001894525

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apimeds Pharmaceuticals US Inc. (APUS) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$6.0M, operating cash flow of -$8.9M, and free cash flow of -$9.0M (-1124.6% YoY). On the balance sheet, APUS closed FY2025 with $164.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$6.0M	-$8.9M	-$9.0M	$164.2M	—
FY2024 (FY)	2024-12-31	$0	-$1.4M	-$733.5K	-$733.5K	$13.1K	—
FY2023 (FY)	2023-12-31	$0	-$777.7K	-$627.8K	-$627.8K	—	—

3. APUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does APUS compare to XBIO and ADXN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for APUS?

Where is APUS trading relative to its 50-day, 200-day, and 52-week technical levels?

APUS last traded at $3.21 (+4.56% on volume of 50,074 shares), positioning the stock -12.30% below its 50-day simple moving average ($3.66) and -70.36% below its 200-day simple moving average ($10.83). Across its 52-week range of $1.51 to $59.70, APUS sits at the 2.9% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.81 to $3.61).

APUS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are APUS insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies APUS leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: APUS RQD Cockpit APUS 12M Forecast APUS Earnings & Move APUS Dividends & DRIP APUS Insiders & 13F APUS Whale Options APUS Profit Sankey APUS News & Why